Allan Finkel – SVP LatAm, Novo Nordisk

Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and why countries in LatAm need to recognise obesity as the disease it is considering its heavy impact on patients’ lives and its links to many other diseases. Finkel also explains how LatAm is now the firm’s fastest growing region across all international operations and delineates his excitement at bringing next-generation Novo Nordisk products to the continent.  
Our job in LatAm is to ensure that the population in general, as well as healthcare providers and governments, understand the importance of diagnosing and treating diabetes early, as well as recognising obesity as a disease to be able to treat it correctly
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report